Risk for SARS-CoV-2 Breakthrough Infection Increased for Cancer Patients
Risk for severe outcomes of COVID-19 higher for patients with hematologic versus solid cancer
Risk for severe outcomes of COVID-19 higher for patients with hematologic versus solid cancer
Specificity for MCED blood test using circulating tumor DNA is 99.1%, and positive predictive value is about 40%
Absolute risk for developing any cancer within 5 years 2% or greater for nearly all those aged 50 years or older
A review of geriatric assessment tools and their role in assessing older patients with cancer before and after treatment.
Total costs increased for breast, lung, prostate cancer; increases in OOP costs for these cancers and colorectal cancer
Some patients do not understand common phrases oncologists use, such as “your tumor is progressing” or “your nodes are positive.”
Risk for aging-related health conditions increased with consumption of more total sugar, added sugar, and sugar-sweetened beverages
Reduction seen in rate of one or more opioid days and in the rate of one or more pain-related hospital events
Increased risk seen for nonscreenable cancers
Among other causes, dapagliflozin treatment reduced the rate of hospitalization due to cancer.